Liquidity Insights from DBV Technologies
DBV Technologies, a clinical-stage biopharmaceutical company dedicated to advancing treatment options for food allergies, recently provided a comprehensive update regarding its liquidity contract with ODDO BHF. This report is an essential resource for investors and stakeholders interested in the financial health and operational efficiency of the company.
Details of the Liquidity Account
As of June 30, 2025, the liquidity account maintained under the contract with ODDO BHF consisted of:
- 210,069 shares of DBV Technologies.
- A monetary balance totaling €171,301.08.
This balance marks a significant development since the inception of the contract on July 1, 2018, when initial assets included:
- 41,159 shares.
- A monetary value of €432,367.25.
Trading Activity Over the Past Six Months
Between January 1, 2025, and June 30, 2025, DBV Technologies engaged in a series of trading activities, with noteworthy statistics that reflect market participation:
- A total of 2,204 buy transactions.
- A total of 2,398 sell transactions.
These activities amounted to significant trading volumes, consisting of:
- 1,156,109 shares and €1,492,280.33 on purchased shares.
- 1,212,908 shares and €1,556,651.52 from sales.
About DBV Technologies
DBV Technologies is at the forefront of research aimed at developing innovative solutions for food allergies and immunologic conditions that sorely need new treatments. The company's dynamic approach revolves around its proprietary technology, the VIASKIN® patch. This method utilizes epicutaneous immunotherapy (EPIT) to enhance patient tolerance to allergens.
Through this non-invasive treatment strategy, the patches deliver minuscule doses of allergens to the immune system, coming into contact with the skin to promote tolerance. This innovative approach aims to educate the immune system, ultimately leading to desensitization. DBV Technologies is fervently devoted to transforming the lives of individuals suffering from food allergies, particularly targeting young children who bear the brunt of these conditions.
The ongoing clinical trials focus on developing therapies for peanut allergies, specifically in toddlers aged 1 to 3 and children aged 4 to 7. This commitment underscores the urgency and importance of addressing food allergies in young populations.
DBV Technologies operates out of Châtillon, France, with a significant presence in North America, specifically in Warren, NJ. The company is publicly traded on Euronext Paris as DBV and on the Nasdaq as DBVT, providing investors access to its shares as it continues to grow and innovate.
Stay Connected with DBV Technologies
For further information about DBV Technologies and its innovative contributions to the biopharmaceutical landscape, visit their official website. Engage with them on their social media channels to stay updated on their ongoing projects and developments.
Frequently Asked Questions
What is the focus of DBV Technologies?
DBV Technologies focuses on developing treatment options for food allergies and other immunologic conditions.
What innovative technology does DBV utilize?
DBV utilizes its proprietary VIASKIN® patch technology that employs epicutaneous immunotherapy for delivering treatment.
How has the liquidity position evolved over time?
The liquidity position has improved significantly since the inception of the contract, reflecting ongoing market engagement and asset growth.
What are DBV’s recent trading activities?
In the first half of 2025, DBV executed over 4,600 transactions, indicating active market participation.
Where can I find more information about DBV Technologies?
More information can be found on their official website and through their social media platforms.
